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Cancer research, treatment, and COVID‑19
Steven A. Curley1*, Frederick Currell2, Sunil Krishnan3 and Zeljka Krpetic4
The COVID-19 pandemic has radically changed the world we live in. The novel coro-
navirus SARS-CoV-2, the infectious agent that causes the disease, is believed to have 
first appeared around December 2019, and in the months since then it has wreaked 
havoc on human communities, health systems, and economies worldwide. At the time of 
writing, it is estimated that more than 12 million individuals have been diagnosed with 
COVID-19, while approximately 550,000 deaths are attributed to the disease (COVID-
19 Dashboard 2020). This has been a topic of constant and intense conversation, quite 
appropriately.
Equally so, there has been a shift in priorities from cancer prevention, treatment and 
research to COVID-19 prevention, treatment and research. As with rebalancing our 
investment portfolios during a financial crisis, we view the current landscape of shifting 
priorities as an opportunity to assess and equilibrate our twin interests in securing the 
quality and quantity of life of our patients and advancing new science with that of navi-
gating the COVID-19 crisis responsibly and resolutely.
Extrapolating from data available from 2018 (Cancer fact sheet 2018), approximately 
9 million patients have been newly diagnosed with a malignant disease in the first half 
of 2020. During that same timeframe, there have been no fewer than 4.75 million deaths 
from cancer throughout the world. At least 43 million people are currently living with a 
diagnosis of cancer and are undergoing a variety of treatments. Clearly, the impact from 
cancer far outstrips that of COVID-19, but does not garner the attention nor sense of 
panic among governments, businesses, the media, and communities. We do not dis-
pute the importance of taking necessary and sometimes radical actions to prevent the 
spread of an infectious disease such as COVID-19, but we must remember as individuals 
involved in looking for better ways to prevent, diagnose, and treat malignant diseases 
that the current impact of cancer on health worldwide far surpasses that of COVID-19.
Cancer is the second leading cause of death globally and its incidence is increas-
ing. As the size of the human population expands worldwide, the number of new 
cases and deaths from cancer annually continues to increase. Cancer can be caused 
by genetic or environmental factors, but also by infectious diseases, such as hepa-
titis B or C virus or human papilloma virus. Furthermore, the COVID-19 crisis has 
directly impacted the care of cancer patients. One of the co-authors of this editorial 
(SK) has recently submitted a paper looking at the effect of COVID-19 on cancer care 
worldwide (Venkatesulu et  al. 2020). In this meta-analysis, patients who are being 
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treated for cancer and who develop COVID-19 have a higher likelihood of intuba-
tion and mortality. The highest mortality risk was among patients with hematologic 
malignancies or lung cancer, but we must remember that many patients being treated 
for cancer are immunosuppressed to some degree owing to their disease-related poor 
nutritional and performance status, cytotoxic chemotherapy, radiation treatments, or 
major surgical procedures.
As editors of Cancer Nanotechnology, we are committed to supporting and pub-
lishing cutting-edge research using nanotechnology as a tool to diagnose and treat 
patients with malignant disease. As an interdisciplinary community at the interface 
of biological science and nanotechnology, we must also use our resources and knowl-
edge as scientists to collaborate with our colleagues who are involved in the extremely 
important work of developing enhanced COVID-19 diagnostics, therapeutics, and 
possibly a vaccine. The HIV crisis of the 1980s and 1990s demonstrated the ability 
of scientists working around the world to develop an understanding of the role of a 
retrovirus in causing AIDS. This collaboration led to the development of successful 
antiviral therapies, with the result that, while there is still no vaccine for HIV, infec-
tion with the virus is no longer a death sentence.
Through similar interdisciplinary collaborations, we remain hopeful and optimis-
tic that we can support and assist our colleagues trying to develop a vaccine active 
against SARS-CoV-2—indeed, some of the underlying concepts and techniques asso-
ciated with cancer treatment and nanotechnology can be readily expanded to support 
this endeavor. As a virus can be nanotechnology and considered a naturally occurring 
nanoparticle, falling into the nanometer size range, we are in the advantageous posi-
tion of being able to translate our knowledge and contribute to the scientific develop-
ment around COVID-19 treatment, prevention and diagnosis and, in particular, to 
advise on safety. Conversely, research put to use in the current pandemic has potential 
to carry across to cancer research. For example, nanotechnology has a tremendous 
potential to mitigate some issues caused by COVID-19, in particular in development 
of advanced personal protective equipment (PPE), allowing vulnerable patients to 
continue receiving treatment for their cancer while the pandemic is ongoing.
It is clear that it is an extraordinary time for scientists around the world, some who 
are working at the forefront of trying to find a treatment for COVID-19 or vaccine for 
the virus causing it, some whose research has been repurposed to focus on this field, 
and some who have simply had to put their research on hold because of lockdowns 
and laboratory closures. We recognize the hardships that a lot of our authors, review-
ers and editorial board members face at this time, and we will therefore take a few 
small steps that we hope will help in some way:
• We will be flexible on deadlines for reviews. Reviewers requiring additional time 
should contact the editorial office or managing editor;
• Where revisions have been requested that require additional, non-essential exper-
iments to be performed, but where the authors cannot currently access their 
laboratories, we are prepared, with guidance from our reviewers, to re-evaluate 
whether the requested experiments are necessary for publication;
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• Where revisions have been requested that require essential experiments to be per-
formed, our teams will work with a more relaxed timeline for completion of the revi-
sions, given the extenuating circumstances that many laboratories face;
• If research that relates to COVID-19 is submitted to the journal, and is within scope, we 
will endeavor to have the research reviewed rapidly, while maintaining quality stand-
ards, to ensure the research to be disseminated quickly to the community. To this end, 
we remind authors that Cancer Nanotechnology encourages posting of preprints of pri-
mary research manuscripts on preprint servers. Authors submitting to the journal alter-
natively have the opportunity to make use of Springer Nature’s free In Review service 
on submission, which allows direct depositing of the research on our partner platform 
Research Square.
There is no doubt that the COVID-19 pandemic will have long-term effects on the land-
scape of research, potentially with greater focus on virology and preventing the next pan-
demic. However, we feel it is important that the scientific and medical community remain 
mindful that cancer is a substantial cause of disease and death throughout the world. The 
community around Cancer Nanotechnology must therefore continue to seek increased 
funding opportunities to promote cancer research and push for better cancer prevention, 
diagnostic, and treatment systems to make them more readily available and affordable for 
all people throughout all socioeconomic classes in the world. While continuing to perform 
our public health duties and working for the greater good, we must work together to reso-
lutely maintain focus on championing evidence-based, patient-facing cancer prevention, 
diagnosis and treatment approaches.
COVID-19 is a disease that has undoubtedly wrought havoc on people’s lives—likewise 
cancer. We owe it to patients not to forget about them, to make their lives more bearable, 
and to give them a chance to live another day.
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